Financial reports
10-Q
2024 Q1
Quarterly report
14 May 24
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2023 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Changes in Registrant's Certifying Accountant
3 Nov 23
8-K
Entry into a Material Definitive Agreement
24 Jul 23
8-K
Entry into a Material Definitive Agreement
21 Jun 21
8-K
Unregistered Sales of Equity Securities
20 Dec 19
8-K
Entry into a Material Definitive Agreement
3 Dec 19
8-K
Entry into a Material Definitive Agreement
6 Nov 19
8-K
Entry into a Material Definitive Agreement
8 Oct 19
8-K
Qrons Announces Upgrade to OTCQB Market
12 Aug 19
8-K
Qrons Appoints Veteran U.s. Based Biotech
27 Jun 19
8-K
Entry into a Material Definitive Agreement
3 May 19
Registration and prospectus
424B3
Prospectus supplement
28 Mar 22
POS AM
Prospectus update (post-effective amendment)
18 Mar 22
424B3
Prospectus supplement
14 Jan 22
S-1/A
IPO registration (amended)
3 Jan 22
S-1
IPO registration
1 Dec 21
D
$500K in equity / options, sold $100K, 3 investors
23 Sep 20
D
$500K in debt / options, sold $25K, 1 investor
18 Dec 19
D
$1M in equity / options
21 May 19
424B3
Prospectus supplement
23 Mar 18
POS AM
Prospectus update (post-effective amendment)
15 Mar 18
Other
EFFECT
Notice of effectiveness
22 Mar 22
EFFECT
Notice of effectiveness
11 Jan 22
CORRESP
Correspondence with SEC
6 Jan 22
UPLOAD
Letter from SEC
15 Dec 21
CT ORDER
Confidential treatment order
7 Aug 18
EFFECT
Notice of effectiveness
22 Mar 18
CT ORDER
Confidential treatment order
22 Nov 17
EFFECT
Notice of effectiveness
10 May 17
CORRESP
Correspondence with SEC
8 May 17
CORRESP
Correspondence with SEC
17 Apr 17